Shunya Ohmura

This study identifies synergistic effects of second-generation RRM2 and CHK1 inhibitors in neuroblastoma and sarcomas, showing enhanced replication stress and apoptosis.

This study shows that reduced EWSR1::ETS activity in Ewing sarcoma promotes immune evasion via the tryptophan-kynurenine-AHR axis, leading to worse clinical outcomes and tumor progression.

The paper identifies CACNA2D2 as a super-enhancer-driven target of EWSR1::WT1 and demonstrates its utility as a diagnostic biomarker for DSRCT.

This study improves Ewing sarcoma cell culture conditions to better reflect physiological states, revealing metabolic gene signatures linked to oncogenic fusion proteins.

This study investigates how SMARCB1 loss in Epithelioid Sarcoma rewires epigenetic regulation, revealing therapeutic vulnerabilities through functional multi-omics analysis.

This study identifies GLRX3 as a vulnerability in Ewing sarcoma driven by EWSR1::FLI1 fusion oncoproteins, showing its role in oxidative stress and iron homeostasis and potential therapeutic targeting.

The paper presents a multi-omics cell line atlas for Ewing sarcoma, identifying new target genes and regulatory mechanisms of EWSR1-ETS fusion oncogenes.